Recent advances in managing gastrointestinal stromal tumor

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gastrointestinal stromal tumors (GISTs) are primarily driven by activating mutations in receptor tyrosine kinases, specifically KIT and platelet-derived growth factor receptor alpha (PDGFRα).
• GISTs represent a key model for understanding and targeting oncogenic kinase-driven cancers.
• The precise understanding of GIST pathogenesis has led to the development of targeted therapies.

Purpose of the Study:

• To review the current standard of care for pharmacotherapy in managing GISTs.
• To discuss the role of targeted therapies in both localized and metastatic settings.
• To provide an overview of treatment strategies for GIST patients.

Main Methods:

• Literature review of current clinical guidelines and landmark studies.
• Analysis of pharmacotherapeutic options for GIST management.
• Synthesis of data on efficacy and safety of targeted agents.

Main Results:

• Pharmacotherapy, particularly tyrosine kinase inhibitors, is the cornerstone of GIST management.
• Targeted agents have significantly improved outcomes for patients with both localized and metastatic disease.
• Treatment strategies are tailored based on mutation status, disease stage, and prior therapies.

Conclusions:

• Targeted inhibition of KIT and PDGFRα has revolutionized GIST treatment.
• Current pharmacotherapy offers effective options for localized and advanced GIST.
• Ongoing research continues to refine treatment approaches for GIST patients.